Company / Financials
RIGEL PHARMACEUTICALS INC Financials
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$294.3M
FY2025 · +64.1% YoY
Net Income
$367.0M
FY2025 · +1999.1% YoY
Profit Margin
124.7%
FY2025 · net income / revenue
ROE
93.8%
FY2025 · return on equity
Total Assets
$513.6M
FY2025
Total Debt
$52.5M
0.13x debt/equity
Equity
$391.5M
FY2025
ROA
71.5%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- Altman Z-Score 1.19 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$294.3M+64.1% YoYNet Income HistoryProfit after all expenses and taxes$367.0M+1999.1% YoYGross Profit HistoryRevenue minus cost of goods sold$7.9MCost of Revenue HistoryDirect costs of producing goods and services sold$19.6M+5.2% YoYOperating Income HistoryProfit from core business operations before interest and taxes$125.5M+418.6% YoYSG&A Expense HistorySelling, general, and administrative expenses$115.9M+2.5% YoYR&D Expense HistoryResearch and development spending$33.3M+42.4% YoYInterest Expense HistoryCost of borrowing and debt obligations$7.9M0.0% YoYIncome Tax HistoryTotal income tax expense-$245.2M-27931.7% YoYEPS (Basic) HistoryBasic earnings per share-$1.44+58.1% YoY